NO20021329D0 - Kinaseinhibitorer som terapeutiske midler - Google Patents

Kinaseinhibitorer som terapeutiske midler

Info

Publication number: NO20021329D0
Authority: NO; Norway
Prior art keywords: therapeutic agents; kinase inhibitors; kinase; inhibitors; therapeutic
Prior art date: 1999-09-17

Application number

NO20021329A

Other languages

English (en)

Other versions

NO20021329L (no

Inventor

Gavin C Hirst

Paul Rafferty

David Calderwood

Helen Louise Twigger

Stephen St Gallay

Kurt Ritter

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-17

Filing date

2002-03-18

Publication date

2002-03-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22552056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021329(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-18 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2002-03-18 Publication of NO20021329D0 publication Critical patent/NO20021329D0/no

2002-05-21 Publication of NO20021329L publication Critical patent/NO20021329L/no

Links

239000003814 drug Substances 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20021329A 1999-09-17 2002-03-18 Kinaseinhibitorer som terapeutiske midler NO20021329L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15461899P	1999-09-17	1999-09-17
PCT/US2000/025357 WO2001019828A2 (en)	1999-09-17	2000-09-15	Kinase inhibitors as therapeutic agents

Publications (2)

Publication Number	Publication Date
NO20021329D0 true NO20021329D0 (no)	2002-03-18
NO20021329L NO20021329L (no)	2002-05-21

Family

ID=22552056

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021329A NO20021329L (no)	1999-09-17	2002-03-18	Kinaseinhibitorer som terapeutiske midler

Country Status (27)

Country	Link
EP (1)	EP1268481B1 (no)
JP (1)	JP2003509427A (no)
KR (1)	KR20020063854A (no)
CN (1)	CN1390220A (no)
AR (1)	AR029766A1 (no)
AT (1)	ATE380814T1 (no)
AU (1)	AU7491400A (no)
BG (1)	BG106585A (no)
BR (1)	BR0014075A (no)
CA (1)	CA2385769A1 (no)
CY (1)	CY1107886T1 (no)
CZ (1)	CZ2002934A3 (no)
DE (1)	DE60037455T2 (no)
DK (1)	DK1268481T3 (no)
ES (1)	ES2299434T3 (no)
HK (1)	HK1053831A1 (no)
HU (1)	HUP0303363A2 (no)
IL (1)	IL148719A0 (no)
MX (1)	MXPA02002938A (no)
NO (1)	NO20021329L (no)
NZ (1)	NZ517759A (no)
PL (1)	PL354241A1 (no)
PT (1)	PT1268481E (no)
SK (1)	SK3792002A3 (no)
TR (1)	TR200201506T2 (no)
WO (1)	WO2001019828A2 (no)
ZA (1)	ZA200202122B (no)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en)	2000-10-23	2005-12-22	Smithkline Beecham Corporation	Novel compounds
AU2002333524A1 (en)	2001-09-11	2003-03-24	Glaxosmithkline K.K.	Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
AU2003211428A1 (en) *	2002-02-22	2003-09-09	Teijin Limited	Pyrrolopyrimidine derivative
US20030225273A1 (en) *	2002-03-21	2003-12-04	Michaelides Michael R.	Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7560552B2 (en)	2002-03-21	2009-07-14	Abbott Laboratories	Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
KR20040103972A (ko)	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
ATE323702T1 (de)	2002-08-06	2006-05-15	Astrazeneca Ab	Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US7592352B2 (en)	2003-05-06	2009-09-22	Smithkline Beecham Corporation	Substituted thieno and furo-pyridines
US7297709B2 (en)	2003-05-22	2007-11-20	Abbott Laboratories	Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7129260B2 (en)	2003-06-02	2006-10-31	Abbott Laboratories	Isoindolinone kinase inhibitors
US7202363B2 (en)	2003-07-24	2007-04-10	Abbott Laboratories	Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) *	2003-07-24	2005-02-03	Patrick Betschmann	Thienopyridine and furopyridine kinase inhibitors
AU2004260689B8 (en) *	2003-07-29	2008-05-15	Irm Llc	Compounds and compositions as protein kinase inhibitors
JP2007517052A (ja) *	2003-12-23	2007-06-28	ノバルティスアクチエンゲゼルシャフト	二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
TW200530236A (en) *	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
EP1751119A1 (en) *	2004-05-19	2007-02-14	AstraZeneca AB	Novel fused heterocycles and uses thereof
FR2871158A1 (fr)	2004-06-04	2005-12-09	Aventis Pharma Sa	Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20070054916A1 (en) *	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
ATE554087T1 (de)	2004-10-29	2012-05-15	Abbott Lab	Neue kinaseinhibitoren
DE102004061288A1 (de) *	2004-12-14	2006-06-29	Schering Ag	3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
PE20061119A1 (es)	2005-01-19	2006-11-27	Aventis Pharma Sa	PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EP1683796A1 (en) *	2005-01-24	2006-07-26	Schering Aktiengesellschaft	Pyrazolopyridines, their preparation and their medical use
US7842809B2 (en)	2005-01-24	2010-11-30	Bayer Schering Pharma Ag	Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
MY145281A (en)	2005-03-25	2012-01-13	Glaxo Group Ltd	Novel compounds
UY29439A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
AU2006229995A1 (en)	2005-03-25	2006-10-05	Glaxo Group Limited	Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
JP2008535822A (ja)	2005-03-25	2008-09-04	グラクソグループリミテッド	新規化合物
US7884109B2 (en)	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
US7795248B2 (en) *	2005-05-18	2010-09-14	Abbott Laboratories, Inc.	Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors
FR2889526B1 (fr)	2005-08-04	2012-02-17	Aventis Pharma Sa	7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102005042742A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CN101305000A (zh) *	2005-09-14	2008-11-12	詹森药业有限公司	作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类
TW200800983A (en) *	2005-09-14	2008-01-01	Janssen Pharmaceutica Nv	5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CA2630271C (en)	2005-11-17	2014-04-08	Osi Pharmaceuticals, Inc.	Fused bicyclic mtor inhibitors
PE20070855A1 (es) *	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619146A2 (pt) *	2005-12-02	2011-09-13	Bayer Pharmaceuticals Corp	derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
EP1981890A2 (en) *	2006-01-25	2008-10-22	OSI Pharmaceuticals, Inc.	UNSATURATED mTOR INHIBITORS
ATE479434T1 (de)	2006-02-14	2010-09-15	Vertex Pharma	Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
US7989459B2 (en)	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20100234351A1 (en) *	2006-02-23	2010-09-16	Takeda Pharmaceutical Company Limited	Fused nitrogen-comprising heterocyclic compound
TW200815437A (en) *	2006-06-13	2008-04-01	Bayer Schering Pharma Ag	Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008022060A2 (en) *	2006-08-14	2008-02-21	Novartis Ag	Imidazo-pyridine derivatives for modulating protein kinase activity
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
TW200831104A (en)	2006-10-04	2008-08-01	Pharmacopeia Inc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en)	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200837064A (en)	2006-10-04	2008-09-16	Pharmacopeia Inc	8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
CN101636399B (zh)	2007-03-22	2012-04-18	武田药品工业株式会社	可用作plk1抑制剂的取代的嘧啶并二氮杂*
MX2009012612A (es)	2007-05-23	2009-12-07	Pharmacopeia Llc	Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
DE102007024470A1 (de)	2007-05-24	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
BRPI0817315A2 (pt)	2007-09-25	2015-03-17	Takeda Pharmaceutical	Inibidores de quinase do tipo polo
EP2072502A1 (de)	2007-12-20	2009-06-24	Bayer Schering Pharma Aktiengesellschaft	Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
CN101239978A (zh) *	2008-03-05	2008-08-13	南方医科大学	一种咪唑并吡啶类化合物
US20100048524A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2719134C (en)	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
WO2009153197A1 (en)	2008-06-18	2009-12-23	F. Hoffmann-La Roche Ag	Halo-substituted pyrimidodiazepines as plkl inhibitors
KR101639642B1 (ko)	2008-12-05	2016-07-14	애브비 바하마스 리미티드	암 치료에 사용하기 위한 키나제 억제제로서의 티에노［3,2-ｃ］피리딘 유도체
EP2393827B1 (en)	2009-02-05	2015-10-07	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011019780A1 (en) *	2009-08-11	2011-02-17	Bristol-Myers Squibb Company	Azaindazoles as btk kinase modulators and use thereof
MX2012003484A (es)	2009-09-25	2012-04-20	Vertex Pharma	Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
SG179207A1 (en)	2009-09-25	2012-04-27	Vertex Pharma	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
US8658794B2 (en)	2010-02-08	2014-02-25	Merck Sharp & Dohme B.V.	8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
US8940725B2 (en)	2010-05-31	2015-01-27	Ono Pharmaceutical Co., Ltd.	Purinone derivative
AU2015202128B2 (en) *	2010-05-31	2015-05-28	Ono Pharmaceutical Co., Ltd.	Purinone derivative
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CN103889987B (zh)	2011-07-19	2016-09-14	默沙东有限责任公司	作为btk抑制剂的选择的咪唑并吡嗪类
US8436179B2 (en)	2011-07-20	2013-05-07	Abbvie Inc.	Kinase inhibitor with improved solubility profile
BR112014012727B1 (pt) *	2011-11-29	2022-10-25	Ono Pharmaceutical Co., Ltd	Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
CA2862981C (en)	2011-12-15	2020-02-25	Bayer Pharma Aktiengesellschaft	Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
UY34484A (es)	2011-12-15	2013-07-31	Bayer Ip Gmbh	Benzotienilo-pirrolotriazinas disustituidas y sus usos
US8501724B1 (en) *	2012-01-31	2013-08-06	Pharmacyclics, Inc.	Purinone compounds as kinase inhibitors
CA2865021C (en)	2012-02-23	2020-06-30	Bayer Intellectual Property Gmbh	Substituted benzothienyl-pyrrolotriazines and uses thereof
BR112014029718A2 (pt)	2012-05-31	2017-06-27	Pharmascience Inc	inibidores da proteína quinase
CA2782774A1 (en)	2012-07-06	2014-01-06	Pharmascience Inc.	Protein kinase inhibitors
CN105796562A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
CN105796569A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
US9481682B2 (en)	2013-01-23	2016-11-01	Merck Sharp & Dohme Corp.	Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
WO2014113942A1 (en)	2013-01-23	2014-07-31	Merck Sharp & Dohme Corp.	Btk inhibitors
CA2904170A1 (en)	2013-03-14	2014-09-25	University Of Maryland, Baltimore	Androgen receptor down-regulating agents and uses thereof
EP3016953A4 (en) *	2013-07-02	2017-03-01	Pharmacyclics, LLC	Purinone compounds as kinase inhibitors
KR20160058774A (ko)	2013-08-12	2016-05-25	토카이 파마슈티컬, 아이엔씨.	안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CA2833701A1 (en) *	2013-11-19	2015-05-19	Pharmascience Inc.	Protein kinase inhibitors
CA2833867A1 (en) *	2013-11-21	2015-05-21	Pharmascience Inc.	Protein kinase inhibitors
EP3076974A1 (en)	2013-12-05	2016-10-12	Acerta Pharma B.V.	Therapeutic combination of a pi3k inhibitor and a btk inhibitor
US9834554B2 (en)	2013-12-20	2017-12-05	Merck Sharp & Dohme Corp.	BTK inhibitors
US9637486B2 (en)	2013-12-20	2017-05-02	Merck Sharp & Dohme Corp.	Btk inhibitors
US10428331B2 (en)	2014-01-16	2019-10-01	Musc Foundation For Research Development	Targeted nanocarriers for the administration of immunosuppressive agents
US10272083B2 (en)	2014-01-21	2019-04-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015146159A1 (en)	2014-03-25	2015-10-01	Ono Pharmaceutical Co., Ltd.	Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
US9937171B2 (en)	2014-04-11	2018-04-10	Acerta Pharma B.V.	Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015193740A2 (en)	2014-06-17	2015-12-23	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
SMT202100674T1 (it)	2014-08-11	2022-01-10	Acerta Pharma Bv	Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
WO2016106623A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Benzamide imidazopyrazine btk inhibitors
WO2016106629A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Btk inhibitors
WO2016106626A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106624A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106628A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Btk inhibitors
JP6750613B2 (ja)	2015-04-09	2020-09-02	小野薬品工業株式会社	プリノン誘導体の製造方法
IL293821A (en)	2015-07-02	2022-08-01	Acerta Pharma Bv	Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
CN105130932B (zh) *	2015-07-14	2017-06-16	中国科学院微生物研究所	化合物及其在制备ptp1b抑制剂和治疗和/或预防ⅱ型糖尿病的药物的用途
WO2017035366A1 (en)	2015-08-26	2017-03-02	Incyte Corporation	Pyrrolopyrimidine derivatives as tam inhibitors
TWI828027B (zh)	2016-03-28	2024-01-01	美商英塞特公司	作為tam抑制劑之吡咯并三嗪化合物
US20180072741A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyrimidine compounds and uses thereof
AR109596A1 (es)	2016-09-09	2018-12-26	Incyte Corp	Compuestos pirazolopiridina y sus usos
US10280164B2 (en)	2016-09-09	2019-05-07	Incyte Corporation	Pyrazolopyridone compounds and uses thereof
US20180072718A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
WO2018152220A1 (en)	2017-02-15	2018-08-23	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
US10633387B2 (en)	2017-09-27	2020-04-28	Incyte Corporation	Salts of TAM inhibitors
DK3755703T3 (da)	2018-02-20	2022-06-27	Incyte Corp	N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10752635B2 (en)	2018-02-20	2020-08-25	Incyte Corporation	Indazole compounds and uses thereof
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
ES3031110T3 (en)	2018-06-29	2025-07-04	Incyte Corp	Formulations of an axl/mer inhibitor
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
WO2020068729A1 (en)	2018-09-25	2020-04-02	Incyte Corporation	Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
KR20220059480A (ko)	2019-08-06	2022-05-10	인사이트 코포레이션	고체 형태의 hpk1 억제제
PH12022552347A1 (en)	2020-03-06	2024-01-29	Incyte Corp	Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2024240088A1 (en) *	2023-05-19	2024-11-28	Chengdu Anticancer Bioscience , Ltd.	Compounds, compositions and methods of treating disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9808281A (pt) *	1997-03-19	2000-05-16	Basf Ag	Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
UA71945C2 (en) *	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents

2000
- 2000-09-15 HK HK03104425.4A patent/HK1053831A1/zh unknown
- 2000-09-15 CA CA002385769A patent/CA2385769A1/en not_active Abandoned
- 2000-09-15 JP JP2001523405A patent/JP2003509427A/ja not_active Withdrawn
- 2000-09-15 DE DE60037455T patent/DE60037455T2/de not_active Expired - Lifetime
- 2000-09-15 DK DK00963510T patent/DK1268481T3/da active
- 2000-09-15 MX MXPA02002938A patent/MXPA02002938A/es unknown
- 2000-09-15 IL IL14871900A patent/IL148719A0/xx unknown
- 2000-09-15 TR TR2002/01506T patent/TR200201506T2/xx unknown
- 2000-09-15 NZ NZ517759A patent/NZ517759A/en unknown
- 2000-09-15 CZ CZ2002934A patent/CZ2002934A3/cs unknown
- 2000-09-15 AT AT00963510T patent/ATE380814T1/de active
- 2000-09-15 ES ES00963510T patent/ES2299434T3/es not_active Expired - Lifetime
- 2000-09-15 CN CN00815776A patent/CN1390220A/zh active Pending
- 2000-09-15 PT PT00963510T patent/PT1268481E/pt unknown
- 2000-09-15 PL PL00354241A patent/PL354241A1/xx not_active Application Discontinuation
- 2000-09-15 HU HU0303363A patent/HUP0303363A2/hu unknown
- 2000-09-15 BR BR0014075-9A patent/BR0014075A/pt not_active IP Right Cessation
- 2000-09-15 EP EP00963510A patent/EP1268481B1/en not_active Expired - Lifetime
- 2000-09-15 WO PCT/US2000/025357 patent/WO2001019828A2/en not_active Ceased
- 2000-09-15 SK SK379-2002A patent/SK3792002A3/sk unknown
- 2000-09-15 KR KR1020027003507A patent/KR20020063854A/ko not_active Withdrawn
- 2000-09-15 AU AU74914/00A patent/AU7491400A/en not_active Abandoned
- 2000-09-18 AR ARP000104887A patent/AR029766A1/es unknown
2002
- 2002-03-14 ZA ZA200202122A patent/ZA200202122B/en unknown
- 2002-03-18 NO NO20021329A patent/NO20021329L/no not_active Application Discontinuation
- 2002-04-05 BG BG106585A patent/BG106585A/xx unknown
2008
- 2008-02-14 CY CY20081100173T patent/CY1107886T1/el unknown

Also Published As

Publication number	Publication date
CZ2002934A3 (cs)	2002-07-17
BR0014075A (pt)	2002-07-16
HUP0303363A2 (hu)	2004-07-28
EP1268481A2 (en)	2003-01-02
SK3792002A3 (en)	2003-09-11
JP2003509427A (ja)	2003-03-11
ATE380814T1 (de)	2007-12-15
AU7491400A (en)	2001-04-17
HK1053831A1 (zh)	2003-11-07
MXPA02002938A (es)	2004-12-06
WO2001019828A3 (en)	2001-10-04
PT1268481E (pt)	2008-03-19
DK1268481T3 (da)	2008-05-05
CY1107886T1 (el)	2013-06-19
DE60037455D1 (de)	2008-01-24
KR20020063854A (ko)	2002-08-05
ES2299434T3 (es)	2008-06-01
ZA200202122B (en)	2003-08-27
NZ517759A (en)	2004-04-30
PL354241A1 (en)	2003-12-29
CA2385769A1 (en)	2001-03-22
IL148719A0 (en)	2002-09-12
EP1268481B1 (en)	2007-12-12
TR200201506T2 (tr)	2002-10-21
BG106585A (en)	2003-03-31
NO20021329L (no)	2002-05-21
CN1390220A (zh)	2003-01-08
AR029766A1 (es)	2003-07-16
WO2001019828A2 (en)	2001-03-22
DE60037455T2 (de)	2008-11-27

Legal Events

Date	Code	Title	Description
2005-01-17	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20021329L (no)	2002-05-21	Kinaseinhibitorer som terapeutiske midler
NO20021239D0 (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
PT1226136E (pt)	2005-04-29	Inibidores da tirosina quinase
DK1212327T3 (da)	2003-12-15	Pyrazolopyrimidiner som terapeutiske midler
NO20023828L (no)	2002-09-30	Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1140840T3 (da)	2006-07-31	omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
ATE318603T1 (de)	2006-03-15	Pyrrolotriazin kinasehemmer
NO20015065D0 (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
EP1296697A4 (en)	2005-02-16	Therapeutic agents - i
NO20031006D0 (no)	2003-03-04	Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
NO20021400D0 (no)	2002-03-20	Terapeutiske konazolinderivater
NO20034176D0 (no)	2003-09-19	Pyrazolopyrimidiner som terapeutiske midler
NO20034177L (no)	2003-11-21	Pyrazolopyrimidiner som terapeutiske midler
DK1337527T3 (da)	2010-01-04	Indolylmaleinimidderivater som proteinkinase C-inhibitorer
ATE237329T1 (de)	2003-05-15	Metalloprotease inhibitoren
ID30460A (id)	2001-12-06	Inhibitor-inhibitor protein siklik tirosin kinase
NO20022692L (no)	2002-08-07	Terapeutiske midler
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20014243D0 (no)	2001-08-31	Dihetero-substituerte metalloprotease inhibitorer
NO20021959D0 (no)	2002-04-25	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20016301D0 (no)	2001-12-21	Terapeutiske midler
DK1690853T3 (da)	2010-06-07	Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer
SI1268481T1 (sl)	2008-06-30	Inhibitorji kinaze kot zdravila
IDP000027420A (id)	2001-12-20	Inhibitor-inhibitor kinase pirolotriazin